公开(公告)号：US10034851B2

公开(公告)日：2018-07-31

申请号：US15045511

申请日：2016-02-17

申请人： IHI Corporation ,  Yoshihiro Ishikawa

发明人： Yoshihiro Ishikawa ,  Haruki Eguchi

IPC分类号： A61K31/295 ,  A61K31/555 ,  A61K9/06 ,  A61M35/00 ,  A61M19/00 ,  C07F15/02 ,  A61K31/28 ,  A61K31/566 ,  A61K31/661 ,  A61K31/7135 ,  A61K38/12 ,  A61K47/48 ,  A61K9/00 ,  A61F7/00

CPC分类号： A61K31/295 ,  A61F2007/009 ,  A61K9/0014 ,  A61K9/06 ,  A61K31/28 ,  A61K31/555 ,  A61K31/566 ,  A61K31/661 ,  A61K31/7135 ,  A61K38/12 ,  A61K47/54 ,  A61K47/542 ,  A61K47/545 ,  A61K47/547 ,  A61K47/551 ,  A61K47/554 ,  A61K47/558 ,  A61K47/61 ,  A61K47/62 ,  A61K47/64 ,  A61M19/00 ,  A61M35/00 ,  C07F15/025

摘要： A metal-salen complex compound, which exhibits excellent noninvasiveness and can be efficiently transferred to an affected site, a local anesthetic containing this metal-salen complex compound, and an antineoplastic drug containing this metal-salen complex compound are provided. Regarding the metal-salen complex compound, a metal atom part in each of two molecules of a metal-salen complex or a derivative of the metal-salen complex is dimerized via water, and the metal-salen complex compound is mixed with a base to produce an ointment.

公开(公告)号：US20170340657A1

公开(公告)日：2017-11-30

申请号：US15666528

申请日：2017-08-01

申请人： Bruce W. Kneller

发明人： Bruce W. Kneller

IPC分类号： A61K31/7016 ,  A61K38/05 ,  A61K33/00 ,  A61K31/70 ,  A61K9/00 ,  A61K31/566 ,  A61K31/197 ,  A61K31/122 ,  A61K45/06 ,  A61K31/7076

CPC分类号： A61K31/7016 ,  A61K9/0019 ,  A61K31/122 ,  A61K31/197 ,  A61K31/566 ,  A61K31/70 ,  A61K31/7076 ,  A61K33/00 ,  A61K38/05 ,  A61K45/06

摘要： The present invention is directed to a dietary supplement comprising palatinose or a derivative thereof. The dietary supplement may be a nutritional product, a sports performance product, a weight loss product or a meal replacement product. The present invention is also directed to a method of increasing the absorption of a compound into the bloodstream, cells and tissue comprising administering palatinose, or a derivative thereof, in combination with the compound. The present invention also relates to a diluent for parenteral compounds. The diluent comprises palatinose or a derivative thereof. Another aspect of the present invention is directed to a method of decreasing the recovery time to pre-performance levels of total adenosine triphosphate (ATP) levels in a mammal comprising administering palatinose or a derivative thereof, to the mammal. The present invention is further directed to a method of supplying a compound to a diabetic patient, burn victim patient or trauma victim patient. The method comprises administering palatinose, or a derivative thereof, in combination with the compound.

公开(公告)号：US20170340651A1

公开(公告)日：2017-11-30

申请号：US15399992

申请日：2017-01-06

申请人： THE BRAIN HEALTH PROJECT LLC

发明人： Morris NOTELOVITZ

IPC分类号： A61K31/593 ,  A61K31/5685 ,  A61K31/566 ,  A23L33/105 ,  A23L33/10 ,  A61K31/435 ,  A61K31/438 ,  A23L33/155 ,  A61K45/06 ,  A61K31/522

CPC分类号： A61K31/593 ,  A23L33/10 ,  A23L33/105 ,  A23L33/155 ,  A23V2002/00 ,  A61K31/435 ,  A61K31/438 ,  A61K31/522 ,  A61K31/566 ,  A61K31/5685 ,  A61K45/06 ,  A61K2300/00 ,  A23V2200/322 ,  A23V2250/2108 ,  A23V2250/71

摘要： The present disclosure provides compositions and formulations comprising botanicals and natural compounds for the promotion of healthy brain aging in adults and for prevention or inhibition of age associated neurodegenerative changes resulting in cognitive, memory and executive dysfunction including modulation of the age related predisposition to mild cognitive impairment, Alzheimer's disease, hormonal and other dementia related conditions. The present disclosure also provides methods of using the compositions and formulations in treating and preventing neurodegenerative changes resulting in cognitive, memory and executive dysfunction.

公开(公告)号：US20170266207A1

公开(公告)日：2017-09-21

申请号：US15475626

申请日：2017-03-31

申请人： THE BRAIN HEALTH PROJECT, INC.

发明人： Morris NOTELOVITZ

IPC分类号： A61K31/593 ,  G01N33/68 ,  A61K31/566 ,  A61K31/353 ,  A61K31/592 ,  A61K31/4748 ,  A23L33/10

CPC分类号： A61K31/593 ,  A23L33/10 ,  A23V2002/00 ,  A61K31/353 ,  A61K31/4748 ,  A61K31/566 ,  A61K31/592 ,  A61K2300/00 ,  G01N33/6896 ,  G01N2800/28 ,  G01N2800/52

摘要： The present disclosure provides compositions and formulations comprising botanicals and natural compounds for the promotion of healthy brain aging in adults, especially adult women, and for prevention of age associated neurodegenerative changes resulting in cognitive, memory and executive dysfunction including modulation of the age related predisposition to mild cognitive impairment, Alzheimer's disease, hormonal and other dementia related conditions. The present disclosure also provides methods of using the compositions and formulations in treating and preventing neurodegenerative changes resulting in cognitive, memory and executive dysfunction.

公开(公告)号：US09724355B2

公开(公告)日：2017-08-08

申请号：US13823078

申请日：2011-09-16

申请人： Henk Swart

发明人： Henk Swart

IPC分类号： A61K31/565 ,  A61K9/20 ,  A61K31/566 ,  A61K47/48 ,  A61K47/40 ,  B82Y5/00 ,  C08B37/16 ,  A61K9/00

CPC分类号： A61K31/565 ,  A61K9/0043 ,  A61K9/0065 ,  A61K9/0095 ,  A61K9/2018 ,  A61K9/2054 ,  A61K31/566 ,  A61K47/40 ,  A61K47/48969 ,  A61K47/549 ,  A61K47/6951 ,  B82Y5/00 ,  C08B37/0015

摘要： Provided are inclusion complexes comprising fulvestrant and a cyclodextrin. The complexes may be useful for treating various conditions, such as cancer and systemic lupus crythematosus. Also provided are methods of producing the inclusion complexes, methods of using the inclusion complexes in therapy, and kits and unit dosages comprising the complexes.

公开(公告)号：US20170051361A1

公开(公告)日：2017-02-23

申请号：US15346197

申请日：2016-11-08

申请人： Memorial Sloan-Kettering Cancer Center

发明人： Mary Ellen Moynahan ,  Alice Gaskell

IPC分类号： C12Q1/68 ,  A61K31/566 ,  A61K31/4196

CPC分类号： C12Q1/6886 ,  A61K31/4196 ,  A61K31/566 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/158

摘要： The presently disclosed subject matter relates to the use of one or more biomarkers to evaluate whether a PI3Kα inhibitor would produce an anti-cancer effect in a subject during the course of treatment with a PI3Kα inhibitor. It is based, at least in part, on the discovery that certain nucleotides can be isolated from the serum of patients undergoing cancer treatment and can be used as a biomarker to indicate the effectiveness of PI3K treatment on cancer growth. Accordingly, in a non-limiting embodiment, a method for determining whether an anti-cancer effect is likely being produced in a cancer by a PI3Kα inhibitor, comprises determining the presence and/or level of one or more PIK3CA biomarkers in one or more samples serially obtained during PI3Kα inhibitor treatment, where if the presence and/or level of a PIK3CA biomarker is increased, it is less likely that the PI3Kα inhibitor is having an anti-cancer effect on the cancer.

摘要翻译： 目前公开的主题涉及使用一种或多种生物标志物来评估在用PI3Kα抑制剂治疗过程中PI3Kα抑制剂是否会在受试者中产生抗癌作用。 至少部分地基于这样的发现，即可以从接受癌症治疗的患者的血清中分离出某些核苷酸，并且可以用作生物标志物来指示PI3K治疗对癌症生长的有效性。 因此，在非限制性实施方案中，确定PI3Kα抑制剂是否可能在癌症中产生抗癌作用的方法包括测定一种或多种样品中一种或多种PIK3CA生物标志物的存在和/或水平 在PI3Kα抑制剂治疗期间连续获得，如果PIK3CA生物标志物的存在和/或水平增加，PI3Kα抑制剂对癌症具有抗癌作用就不太可能。

公开(公告)号：US20170049836A1

公开(公告)日：2017-02-23

申请号：US15084109

申请日：2016-03-29

申请人： FEM MED FORMULAS LIMITED PARTNERSHIP

发明人： Krista COVENTRY

IPC分类号： A61K36/79 ,  A61K36/28 ,  A61K31/566 ,  A61K31/365 ,  A61K31/593 ,  A61K31/404 ,  A61K36/185

CPC分类号： A61K36/79 ,  A61K31/194 ,  A61K31/365 ,  A61K31/404 ,  A61K31/566 ,  A61K31/59 ,  A61K31/593 ,  A61K36/15 ,  A61K36/185 ,  A61K36/28 ,  A61K45/06 ,  A61K2300/00

摘要： A composition comprising_indole-3-carbinol, milk thistle, schizandra, stinging nettle, hydroxymatairesinol ligands and optionally calcium-d-glucarate and 400 KJ Vitamin D for altering urinap estrone metabolite and preventing breast cancer in pre and post menopausal women.

摘要翻译： 包含_吲哚-3-甲醇，乳蓟，五味子三明治，刺荨麻，羟基苦参醇配体和任选的钙-d-葡糖二酸和400KJ维生素D，用于改变尿囊素雌酮代谢物，并预防绝经后妇女和绝经后妇女的乳腺癌。

公开(公告)号：US20170042910A1

公开(公告)日：2017-02-16

申请号：US15307198

申请日：2015-04-27

申请人： The Regents of the University of California

发明人： Rhonda R. Voskuhl

IPC分类号： A61K31/566 ,  A61K9/00 ,  A61K31/57

CPC分类号： A61K31/566 ,  A61K9/0053 ,  A61K31/57 ,  A61K45/06 ,  A61K2300/00

摘要： This invention relates to novel packaged pharmaceutical products for the treatment of neurodegenerative diseases, such as multiple sclerosis, and methods of using these products.

摘要翻译： 本发明涉及用于治疗神经变性疾病如多发性硬化症的新型包装药物产品和使用这些产品的方法。

公开(公告)号：US20160367568A1

公开(公告)日：2016-12-22

申请号：US15256686

申请日：2016-09-05

申请人： Juneau Biosciences, LLC

发明人： Kenneth Ward ,  Rakesh N. Chettier ,  Hans M. Albertsen

IPC分类号： A61K31/566

CPC分类号： A61K31/566 ,  C12Q1/6883 ,  C12Q2600/156

摘要： The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis and the use of such risk information in selectively administering a treatment that at least partially prevents or compensates for an endometriosis related symptom.

公开(公告)号：US09517240B2

公开(公告)日：2016-12-13

申请号：US13970223

申请日：2013-08-19

申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

发明人： Eva Y. H. P. Lee

IPC分类号： A61K31/56 ,  A61K31/575 ,  A61K31/567 ,  A61K31/138 ,  A61K31/565 ,  A61K31/58 ,  A61K31/566

CPC分类号： A61K31/575 ,  A61K31/138 ,  A61K31/56 ,  A61K31/565 ,  A61K31/566 ,  A61K31/567 ,  A61K31/58 ,  A61K2300/00

摘要： The present invention provides methods of preventing or delaying the development of cancer (e.g., breast cancer) in BRCA1 mutation positive patients by beginning progesterone receptor antagonist treatment at an early age (e.g., by age 35, 30, or 25). In certain embodiment, such early treatment is long-term treatment, which may substitute or delay a preventative ovariectomy, single or double mastectomy (e.g., in patients wishing to delay or avoid a mastectomy, or patients that cannot afford a mastectomy).

摘要翻译： 本发明提供了通过在早期（例如，35,30或25岁）开始孕酮受体拮抗剂治疗来预防或延迟BRCA1突变阳性患者中癌症（例如乳腺癌）发展的方法。 在某些实施方案中，这种早期治疗是长期治疗，其可以代替或延迟预防性卵巢切除术，单或双乳房切除术（例如，希望延迟或避免乳房切除术的患者或不能承受乳房切除术的患者）。